Prostate Cancer

Five treatments. Reduced risk of side effects.

Prostate cancer is the second most common cancer in men worldwide.1

Today, MRIdian is changing the paradigm for prostate cancer treatment and may offer patients the ability to treat their cancer with just five fractions and fewer side effects.

Prostate patients treated with MRIdian SBRT have no early grade 3 GI/GU toxicity and a 60 to 90 percent lower grade 2 GI/GU toxicity, as compared to standard LINAC treatments, without the need for fiducials or spacers.2

Better for patients. Better for clinicians. Learn more about MRIdian today.

 

1. Ferlay, J., et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Retrieved August 30, 2019 from https://gco.iarc.fr/today (2018)
2. Bruynzeel A, et al. A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: Early toxicity results International Journal of Radiation Oncology*Biology*Physics. epub 2019; DOI: 10.1016/j.ijrobp.2019.08.007

A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results

In a recent study of MRgRT at Amsterdam UMC, they found that patients with localized prostate cancer observed a low incidence of early GI and GU toxicity, both in clinician- and patient-reported outcome measurements.

Videos Related To Prostate Cancer

Neil Weissman, Prostate Cancer Survivor

Mr. Weissman shares his experience of being diagnosed with prostate cancer and treatment on the MRIdian by Dr. Himanshu Nagar and his team.

April 27, 2020

Jim Roper, Prostate Cancer Survivor

Mr. Roper shares his experience of being diagnosed with prostate cancer and treatment on the MRIdian by Dr. Himanshu Nagar and his team.

March 19, 2020

ViewRay MRIdian for Prostate, Breast, and Pancreatic Cancer Treatment

October 22, 2019

Scientific Presentations Related To Prostate Cancer

MR-Guided Daily Adaptive SBRT for Prostate Cancer – A Phase 2 Prospective Study

Ben Slotman, MD, PhD
Amsterdam University Medical Centers
ASTRO 2019

Dr. Slotman has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

MRI-Guided Prostate RT: See the Cancer, Spare the Toxicity

Himanshu Nagar, MD
The NewYork-Presbyterian Hospital and Weill Cornell Medicine
ASTRO 2019

Dr. Nagar has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

ViewRay SBRT of Prostate: Seeing is Believing

Prof. Jin Ho Kim, MD
Seoul National University Hospital
ASTRO 2019

Dr. Kim has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Novel Applications for MRI-Guided Radiotherapy in the Treatment of Soft Tissue Sarcomas and Prostate Cancer

Zachary Morris, MD, PhD
Carbone Cancer Center, University of Wisconsin
ASTRO 2018

Dr. Morris has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Post-Prostatectomy Radiotherapy: Roles for MRI-Guided RT

Amar Kishan, MD
UCLA Health, Jonsson Comprehensive Cancer Center
ASTRO 2018

Dr. Kishan has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Benefits of MR-Guided Radiotherapy: Initial Clinical Experience with the ViewRay MRIdian System

Minsong Cao, Ph.D.
UCLA Health, Jonsson Comprehensive Cancer Center
AAPM 2018

Dr. Cao has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

On-Table Adaptive MR-Guided SBRT: Clinical Experience at VUmc

Ben Slotman, MD, PhD
VUmc – Amsterdam, The Netherlands
Advanced Applications of MR-Guided Radiotherapy Symposium (Amsterdam, 2018)

Dr. Slotman has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

  Global Info

CUSTOMER LOGIN

Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In
   

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy

Accept